SELLAS Life Sciences (SLS) Other Non-Current Assets (2010 - 2026)
SELLAS Life Sciences' (SLS) quarterly Other Non-Current Assets came in at $255000.0 in Q1 2026, down 3.04% year-on-year from $263000.0 in Q1 2025, and down 0.78% on a QoQ basis from $257000.0 in Q4 2025.
SELLAS Life Sciences (SLS) Other Non-Current Assets (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 17 years of Other Non-Current Assets data on file, last reported at $255000.0 in Q1 2026.
- On a quarterly basis, Other Non-Current Assets fell 3.04% year-over-year to $255000.0 in Q1 2026; TTM through Mar 2026 was $255000.0, a 3.04% decrease from a year earlier, with the FY2025 full-year figure at $257000.0, down 3.38% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $255000.0, down from $257000.0 in the prior quarter.
- Over the last five years, Other Non-Current Assets for SLS reached as high as $554000.0 in Q1 2022 and fell as low as $34000.0 in Q3 2025.
- Historically, Other Non-Current Assets has averaged $313294.1 across 5 years, with a median of $272000.0 in 2024.
- Across the five-year window, Other Non-Current Assets plunged 88.59% in 2024 and decreased 3.04% in 2026, its largest moves.
- Year by year, Other Non-Current Assets stood at $399000.0 in 2022, then plunged by 31.08% to $275000.0 in 2023, then dropped by 3.27% to $266000.0 in 2024, then fell by 3.38% to $257000.0 in 2025, then decreased by 0.78% to $255000.0 in 2026.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $255000.0 in Q1 2026, $257000.0 in Q4 2025, and $34000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | SELLAS Life Sciences | 3.23 Mn | 3.23 Mn | - | 255,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 255,000.00 |
| Dec 31, 2025 | 257,000.00 |
| Sep 30, 2025 | 34,000.00 |
| Jun 30, 2025 | 261,000.00 |
| Mar 31, 2025 | 263,000.00 |
| Dec 31, 2024 | 266,000.00 |
| Sep 30, 2024 | 43,000.00 |
| Jun 30, 2024 | 270,000.00 |
| Mar 31, 2024 | 272,000.00 |
| Dec 31, 2023 | 275,000.00 |
| Sep 30, 2023 | 377,000.00 |
| Jun 30, 2023 | 381,000.00 |
| Mar 31, 2023 | 384,000.00 |
| Dec 31, 2022 | 399,000.00 |
| Sep 30, 2022 | 521,000.00 |
| Jun 30, 2022 | 514,000.00 |
| Mar 31, 2022 | 554,000.00 |
| Dec 31, 2021 | 594,000.00 |
| Sep 30, 2021 | 597,000.00 |
| Jun 30, 2021 | 623,000.00 |